Posted on 02/01/03
Accounting, test woes mar performance
The biotech sector's Nuclear Winter of 2002 -- triggered by a rash of drug testing disappointments and accounting shenanigans that hammered credibility and drove bellwether stock prices down 40 per cent -- isn't showing any signs of a spring thaw.
The full text of this article has 825 words.
To continue reading this article, you will need to purchase this article.
Already have a member account? Login now
Pay-Per-View Offers To read the complete article, select one of the following options
Purchasing from globeandmail.com is quick and secure.
